BMS-986202

BMS-986202 is a potent, selective, and orally active small molecule inhibitor of tyrosine-protein kinase 2 (TYK2), specifically binding to the pseudokinase domain (JH2) of TYK2 with high affinity (IC50 = 0.19 nM, Ki = 0.02 nM)[1][5]. It demonstrates remarkable selectivity over other kinases, including other Janus kinase family members[1][5]. Preclinical studies have shown efficacy in mouse models of IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus[2][4][5]. The drug was developed by Bristol Myers Squibb for the treatment of autoimmune diseases such as psoriasis and has completed early-phase clinical trials in humans[7].